EndoTAG™-1 On Phase II Trials Against Pancreatic Cancer
Filed in archive Drugs, Vaccines and Therapeutics on August 25, 2005
For the second day in a row, I' blogging about Paclitaxel. This time as a therapeutic against pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related mortality in the US.
MediGene AG announced the initiation of a phase II Clinical trial of drug candidate EndoTAGĂ-1 (temporary name), a combination of paclitaxel and a unique carrier system which targets paclitaxel to newly formed blood vessels. EndoTAGďż˝ aims at starving cancerous tumors by destroying blood vessels and thereby cutting off nutrient supply.
Dr. Peter Heinrich, MediGene CEO, says
"Following several phase I/II trials in different indications with 151 patients showing safety and promising efficacy trends of EndoTAGĂ-1, we are continuing the clinical development of this innovative drug candidate. The platform technology EndoTAGďż˝ has a great potential for the treatment of various solid, highly vascularized tumors. Therefore we plan to start further trials in other cancer indications in 2006."
Read MediGene's press release here.
Tags: paclitaxel cancer biotech phase trials pancreatic+cancer against+pancreatic phase+trials
Vote for EndoTAG™-1 On Phase II Trials Against Pancreatic Cancer:
|
Rating: 6.00 out of 4 vote(s) cast.
|
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells